LUC7L

Across TCGA pan-cancer cohorts, LUC7L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LUC7L data layer compared with 18 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LUC7L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LUC7L expression acts as an unfavorable survival marker, although some lineages such as OV and LSCC show a favorable association.

CCRCC, OV, and LSCC are the cancer types where LUC7L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.606	0.860	<.001	34	view →
OV	DFS	Median	All	0.907	0.639	.028	4	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.316	.006	3	view →
UCEC	OS	Tertile	All	1.000	0.904	.029	2	view →
LUAD	DFS	Median	III,IV	0.713	0.286	.026	2	view →
PDAC	DFS	Tertile	All	0.478	0.312	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LUC7L–CCRCC (DFS)

Open the CCRCC breakdown →